Literature DB >> 8885131

Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells.

R Marches1, E Racila, T F Tucker, L Picker, P Mongini, R Hsueh, E S Vitetta, R H Scheuermann, J W Uhr.   

Abstract

Polyclonal anti-IgM antibodies were more effective than monoclonal antibodies in inducing dormancy in SCID mice bearing a murine B lymphoma (BCL1). Under saturating conditions, both polyclonal and monoclonal anti-Ig antibodies induced cell cycle arrest (CCA) in both BCL1 cells and human B lymphoma cells (Daudi) but polyclonal antibodies were far more effective at inducing apoptosis. A mixture of several monoclonal antibodies specific for noncrossreactive epitopes on C mu mimicked the effects of a polyclonal anti-mu. Hypercrosslinking mIgM by a polyclonal antibody against the primary monoclonal anti-mu markedly increased apoptosis and CCA. Hence, the extent of crosslinking of IgM and the resultant singnalling may be a major factor in inducing and maintaining dormancy and in determining whether lymphoma cells respond by apoptosis or CCA. In contrast to mIgM, another B cell receptor, CD40, which induces CCA when crosslinked did not induce apoptosis after hypercrosslinking. The results are consistent with the hypothesis that aspects of the CCA and apoptotic pathways are independent. When anti-CD40 was added with anti-mu to Daudi cells, the proportion of cells undergoing apoptosis was increased.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8885131

Source DB:  PubMed          Journal:  Ther Immunol        ISSN: 0967-0149


  10 in total

1.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Authors:  M A Ghetie; E M Podar; A Ilgen; B E Gordon; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

2.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

3.  Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen.

Authors:  G Gasparini; M Fanelli; P Boracchi; A Morabito; N Locopo; E Biganzoli
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Cancer dormancy and cell signaling: induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells.

Authors:  R Marches; R Hsueh; J W Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.

Authors:  Rhona Stein; Mitchell R Smith; Susan Chen; Maria Zalath; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes.

Authors:  Pavitra Chakravarty; Radu Marches; Neil S Zimmerman; Austin D-E Swafford; Pooja Bajaj; Inga H Musselman; Paul Pantano; Rockford K Draper; Ellen S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-16       Impact factor: 11.205

7.  Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.

Authors:  Robert C Hsueh; Adrienne M Hammill; Jamie A Lee; Jonathan W Uhr; Richard H Scheuermann
Journal:  BMC Immunol       Date:  2002-12-06       Impact factor: 3.615

8.  Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells.

Authors:  M S Cragg; L Zhang; R R French; M J Glennie
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

Review 9.  The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.

Authors:  Emma Risson; Ana Rita Nobre; Veronique Maguer-Satta; Julio A Aguirre-Ghiso
Journal:  Nat Cancer       Date:  2020-07-06

Review 10.  Exploring the pathways to chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Francesco Forconi; Thomas J Kipps
Journal:  Blood       Date:  2021-09-09       Impact factor: 25.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.